Results 141 to 150 of about 17,658 (183)

Management of neovascular age-related macular degeneration

Progress in Retinal and Eye Research, 2007
Neovascular age-related macular degeneration (AMD) is becoming an increasing socio-medical problem as the proportion of the aged population is continuously increasing. However, new insights in the pathogenesis of the disease offer the opportunity to develop targeted therapies that attack the disease process more successfully than ever.
Ursula M, Schmidt-Erfurth, Christian, Pruente   +1 more
openaire   +2 more sources

Neovascular Age-Related Macular Degeneration

Ophthalmology, 2013
Age-related macular degeneration (AMD) progresses through early and intermediate to advanced stages, one of which is neovascular AMD (nAMD). A correct diagnosis of nAMD at an early stage is critical because unlike geographic atrophy, it can be treated with therapeutic agents.
Bianca S. Gerendas, Julia S. Kroisamer, Florian Sulzbacher, Ursula Schmidt-Erfurth   +3 more
openaire   +2 more sources

Ranibizumab for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine, 2006
Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration.In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular ...
Philip J, Rosenfeld, David M, Brown, Jeffrey S, Heier, David S, Boyer, Peter K, Kaiser, Carol Y, Chung, Robert Y, Kim   +6 more
openaire   +2 more sources

Review of Fibrosis in Neovascular Age-Related Macular Degeneration

American Journal of Ophthalmology, 2023
To report the diagnosis and definitions, epidemiology, risk factors, and visual outcomes of fibrosis in neovascular age-related macular degeneration (nAMD).Systematic review and meta-analysis.The review was performed using the Cochrane Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
KAI XIONG CHEONG, CHUI MING GEMMY CHEUNG, KELVIN YI CHONG TEO   +2 more
openaire   +2 more sources

Exudative non-neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology, 2020
To describe the clinical and multimodal imaging (MMI) features of age-related macular degeneration (AMD) eyes presenting with intraretinal exudation and no evidence of neovascularization or structural alterations of native retinal vessels.This was a retrospective review of the MMI and electronic health records for 3 consecutive patients presenting with
Tommaso Bacci, Juliet O. Essilfie, Belinda C. S. Leong, K. Bailey Freund   +3 more
openaire   +3 more sources

Laser photocoagulation for neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews, 2004
Laser photocoagulation was the first treatment introduced to try to halt the progression of neovascular age-related macular degeneration (AMD), in which newly formed vessels or choroidal neovascularisation (CNV) grow under the macula leading to the occurrence of a scotoma or blind spot in the central visual field.The aim of this review was to examine ...
VIRGILI, GIANNI, A. Bini
openaire   +3 more sources

Association of neovascular age-related macular degeneration and hyperhomocysteinemia

American Journal of Ophthalmology, 2004
To assess the relationship between plasma homocysteine levels and exudative neovascular age-related macular degeneration (AMD).Cross-sectional study.A prospective comparative cross-sectional study was conducted in outpatient ophthalmology clinics in a university-affiliated medical institution.
Ruth, Axer-Siegel, Dan, Bourla, Rita, Ehrlich, Gad, Dotan, Yoav, Benjamini, Slava, Gavendo, Dov, Weinberger, Ben-Ami, Sela   +7 more
openaire   +2 more sources

Preferred therapies for neovascular age-related macular degeneration

Current Opinion in Ophthalmology, 2011
This report reviews the current treatment strategies and ongoing clinical trials in the treatment of neovascular age-related macular degeneration (AMD).The functional and anatomic outcomes achieved in the pivotal ranibizumab trials with monthly injections set the standard for comparison.
Allen, Chiang, Carl D, Regillo
openaire   +2 more sources

An update on the pharmacotherapy of neovascular age-related macular degeneration

Expert Opinion on Pharmacotherapy, 2013
Neovascular age-related macular degeneration (AMD) is currently the most common cause of legal blindness in industrialized countries. The advent of pharmacotherapy with intravitreal VEGF inhibitors has greatly improved outcomes for the treatment of this disease.The present review is divided into two major sections: the period prior to the use of anti ...
Freund KB, Mrejen S, Gallego-Pinazo R
openaire   +3 more sources

Proteomics of vitreous in neovascular age-related macular degeneration

Experimental Eye Research, 2016
Neovascular age-related macular degeneration (nAMD) has been described as a predominantly inflammatory and proangiogenic retino-choroidal disease. Vitreous humor (VH) is the adjacent and accessible compartment which, due to the vicinity to the retina, might best represent changes of protein-based mediators of nAMD. The aim of this clinical-experimental
Matthias Nobl, Michael Reich, Ivanka Dacheva, Justyna Siwy, William Mullen, Joost P. Schanstra, Chul Young Choi, Jürgen Kopitz, Florian T.A. Kretz, Gerd U. Auffarth, Frank Koch, Michael J. Koss   +11 more
openaire   +3 more sources